Fundraising FoxPsammiad Therapeutics
Denver, US · Founded 2022 · Delaware corporation
Find your way into Psammiad Therapeutics
Sign up to see every warm intro you have to Psammiad Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Psammiad Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
MV
Matthew VeatchNamed on SEC filing
AG
Anthony GerberNamed on SEC filing
ME
Michael EberNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2022
▶$2.2MraisedFeb 2022 · 5 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2022 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthew VeatchExecutive Officer
- Anthony GerberExecutive Officer, Director
- Michael EberExecutive Officer
- Offering amount
- $3M
- Amount sold
- $2.2M
- Minimum investment
- $10K
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Psammiad Therapeutics raised?
- Psammiad Therapeutics has disclosed $2.2M raised across 1 round.
- Where is Psammiad Therapeutics headquartered?
- Psammiad Therapeutics is headquartered in Denver, US.